Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

406
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
406
Factors Influencing Drug Absorption: Pharmaceutical Parameters01:28

Factors Influencing Drug Absorption: Pharmaceutical Parameters

792
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
792
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226
Precipitation of Ions03:11

Precipitation of Ions

31.3K
Predicting Precipitation
The equation that describes the equilibrium between solid calcium carbonate and its solvated ions is:
31.3K
IV Infusion to Oral Dosing: Conversion Methods01:28

IV Infusion to Oral Dosing: Conversion Methods

169
The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...
169
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism01:21

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism

888
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
888

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bioanalytical Method Development and Validation for the Estimation of Metformin and Vildagliptin in K3EDTA Human Plasma Using HPLCESI- MS/MS.

Drug metabolism and bioanalysis letters·2025
Same author

Validated Stability-Indicating RP-HPLC Method for Nirmatrelvir in Self-Emulsifying Drug Delivery Systems: Formulation Characterization and Permeability Enhancement.

Archiv der Pharmazie·2025
Same author

Crossing Boundaries: A Review of the Diverse Functions of Heterocyclic Compounds in the Management of Cancer and Infectious Diseases.

Current drug targets·2025
Same author

Detailed Comprehensive Review on Advancement of Cubosomes and their Currently Available Applications.

Current pharmaceutical biotechnology·2025
Same author

Determination of doxepin hydrochloride in spiked human plasma and capsule after derivatization with eosin Y using resonance Rayleigh scattering, second-order scattering and frequency doubling scattering methods.

Luminescence : the journal of biological and chemical luminescence·2023
Same author

Monitoring Cardiovascular Problems in Heart Patients Using Machine Learning.

Journal of healthcare engineering·2023

Related Experiment Video

Updated: Apr 17, 2026

Preparation of Quality Inositol Pyrophosphates
10:34

Preparation of Quality Inositol Pyrophosphates

Published on: September 3, 2011

13.8K

Formulation and optimization of potassium iodide tablets.

Antoine Al-Achi1, Binit Patel2

  • 1Campbell University, College of Pharmacy & Health Sciences, P.O. Box 1090, Buies Creek, NC 27506, USA.

Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society
|February 17, 2015
PubMed
Summary
This summary is machine-generated.

Potassium iodide (KI) tablets were developed using direct compression. Optimized formulations demonstrated good pharmaceutical properties, suitable for radiation protection.

Keywords:
Design of experimentDirect compression methodPotassium iodideTablet quality control testsTablets

More Related Videos

Formation of Dispersible Taohong Siwu Tablets
05:44

Formation of Dispersible Taohong Siwu Tablets

Published on: February 3, 2023

2.2K
Synthesis and Purification of Iodoaziridines Involving Quantitative Selection of the Optimal Stationary Phase for Chromatography
10:14

Synthesis and Purification of Iodoaziridines Involving Quantitative Selection of the Optimal Stationary Phase for Chromatography

Published on: May 16, 2014

13.2K

Related Experiment Videos

Last Updated: Apr 17, 2026

Preparation of Quality Inositol Pyrophosphates
10:34

Preparation of Quality Inositol Pyrophosphates

Published on: September 3, 2011

13.8K
Formation of Dispersible Taohong Siwu Tablets
05:44

Formation of Dispersible Taohong Siwu Tablets

Published on: February 3, 2023

2.2K
Synthesis and Purification of Iodoaziridines Involving Quantitative Selection of the Optimal Stationary Phase for Chromatography
10:14

Synthesis and Purification of Iodoaziridines Involving Quantitative Selection of the Optimal Stationary Phase for Chromatography

Published on: May 16, 2014

13.2K

Area of Science:

  • Pharmaceutical Sciences
  • Materials Science

Background:

  • Potassium iodide (KI) is a crucial agent for thyroid protection against radioactive iodine exposure.
  • Direct compression offers an efficient method for tablet formulation.

Purpose of the Study:

  • To develop and optimize a direct compression tablet formulation of potassium iodide (KI).
  • To ensure the formulation meets predetermined physical and pharmaceutical quality standards.

Main Methods:

  • Utilized Design of Experiment (DoE) with mixture design to optimize tablet composition.
  • Employed direct compression for tablet preparation.
  • Scaled-up the formulation using single-punch and rotary mini tablet presses.
  • Conducted comprehensive quality control tests, including photo-stability.

Main Results:

  • An optimal KI tablet formulation (%w/w) was identified: Avicel 48.70%, silicon dioxide 0.27%, stearic acid 1.00%, magnesium stearate 2.45%, dicalcium phosphate 18.69%, and potassium iodide 28.89% (130 mg/tablet).
  • Tablets produced via rotary mini tablet press exhibited favorable pharmaceutical characteristics.
  • Photo-stability testing indicated a shelf-life of 25 days at room temperature when protected from light.

Conclusions:

  • Direct compression is a viable method for producing stable and effective potassium iodide (KI) tablets.
  • The optimized KI tablet formulation possesses suitable pharmaceutical qualities for use as a radioprotective agent.
  • Further studies may explore extended shelf-life and different storage conditions.